Non-specific translocation of peptide-displaying bacteriophage particles across the gastrointestinal barrier

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 2, 2008, Pages 577-581

  Hamzeh Mivehroud, Maryam ^a,b   Mahmoudpour, Ali ^b   Rezazadeh, Hasan ^a   Dastmalchi, Siavoush ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug delivery; M13 phage; Peptide library; Phage display

Indexed keywords

AMINO ACID; COAT PROTEIN; PEPTIDE; PEPTIDE LIBRARY; PIII COAT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE M13; BIOPANNING; BLOOD LEVEL; DRUG DELIVERY SYSTEM; GASTROINTESTINAL MUCOSA; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; SEQUENCE ANALYSIS; SPLEEN;

BACTERIOPHAGE M13; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; PEPTIDE LIBRARY;

EID: 52949103737     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.005     Document Type: Article

References (35)

1. Baumgart D.C., and Dignass A.U. Intestinal barrier function. Curr. Opin. Clin. Nutr. Metabol. Care 5 (2002) 685-694
2. Morishita M., and Peppas N.A. Is the oral route possible for peptide and protein drug delivery?. Drug Discov. Today 11 (2006) 905-910
3. Duerr D.M., White S.J., and Schluesener H.J. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. Methods 116 (2004) 177-180
4. Clark M.A., Jepson M.A., and Hirst B.H. Exploiting M cells for drug and vaccine delivery. Adv. Drug Del. Rev. 50 (2001) 81-106
5. Magalhaes J.G., Tattoli I., and Girardin S.E. The intestinal epithelial barrier: how to distinguish between the microbial flora and pathogens. Semin. Immunol. 19 (2007) 106-115
6. Christensen D.J., Gottlin E.B., Benson R.E., and Hamilton P.T. Phage display for target-based antibacterial drug discovery. Drug Discov. Today 6 (2001) 721-727
7. Ladner R.C., Sato A.K., Gorzelany J., and de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov. Today 9 (2004) 525-529
8. Kamada H., Okamoto T., Kawamura M., Shibata H., Abe Y., Ohkawa A., Nomura T., Sato M., Mukai Y., Sugita T., Imai S., Nagano K., Tsutsumi Y., Nakagawa S., Mayumi T., and Tsutsumi S.-I. Creation of novel cell-penetrating peptides for intracellular drug delivery using systemic phage display technology originated from tat transduction domain. Biol. Pharm. Bull. 30 (2007) 218-223
9. Dennis M.S., Eigenbrot C., Skelton N.J., Ultsch M.H., Santell L., Dwyer M.A., O'Connell M.P., and Lazarus R.A. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 404 (2000) 465-470
10. Hyde-DeRuyscher R., Paige L.A., Christensen D.J., Hyde-DeRuyscher N., Fredericks L.A.Z.L., Kranz J., Gallant P., Zhang J., Rocklage S.M., Fowlkes D.M., Wendler P.A., and Hamilton P.T. Detection of small-molecule enzyme inhibitors with peptides isolated from phage displayed combinatorial peptide libraries. Chem. Biol. 7 (2000) 17-25
11. Hall J.M., Chang C.-Y., and McDonnell D.P. Development of peptide antagonists that target estrogen receptor β-coactivator interactions. Mol. Endocrinol. 14 (2000) 2010-2023
12. Westwater C., Kasman L.M., Schofield D.A., Werner P.A., Dolan J.W., Schmidt M.G., and Norris J.S. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47 (2003) 1301-1307
13. Yacoby I., Bar H., and Benhar I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob. Agents Chemother. 51 (2007) 2156-2163
14. Yacoby I., Shamis M., Bar H., Shabat D., and Benhar I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents Chemother. 50 (2006) 2087-2097
15. Houten N.E., Zwick M.B., Menendez A., and Scott J.K. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 24 (2006) 4188-4200
16. Mohandas J., Marshall J.J., Duggin G.G., Horvath J.S., and Tiller D.J. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res. 44 (1984) 5086-5091
17. Garnier J., Gibrat J.-F., and Robson B. GOR secondary structure prediction method version IV. Methods Enzymol. 266 (1996) 540-553
18. Carugo O. Prediction of polypeptide fragments exposed to the solvent. In Silico Biol. 3 (2003) 35
19. Kyte J., and Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1982) 105-132
20. Abraham D.J., and Leo A.J. Extension of the fragment method to calculate amino acid zwitterion and side chain partition coefficients. Protein. Struct. Funct. Genet. 2 (1987) 130-152
21. Valadon P., Garnett J.D., Testa J.E., Bauerle M., Oh P., and Schnitze J.E. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 407-412
22. Molenaar T.J., Michon I., de Haas S.A., van Berkel T.J., Kuiper J., and Biessen E.A. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 293 (2002) 182-191
23. Samli K.N., McGuire M.J., Newgard C.B., Johnston S.A., and Brown K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes 54 (2005) 2103-2108
24. Papavoine C.H., Christiaans B.E., Folmer R.H., Konings R.N., and Hilbers C.W. Solution structure of the M13 major coat protein in detergent micelles: a basis for a model of phage assembly involving specific residues. J. Mol. Biol. 282 (1998) 401-419
25. Vitiello C.L., Merril C.R., and Adhyaa S. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res. 114 (2005) 101-103
26. Gorski A., Wazna E., Dabrowska B.-W., Dabrowska K., Switala-Jelen K., and Miedzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46 (2006) 313-319
27. Webster R. Filamentous phage biology. In: Barbas C.F., Burton D.R., Scott J.K., and Silverman G.J. (Eds). Phage Display: A Laboratoty Manual (2001), Cold Spring Harbor Laboratory Press, New York 1.1-1.37
28. des Rieux A., Fievez V., Garinot M., Schneider Y.-J., and Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006) 1-27
29. Junga T., Kamm W., Breitenbacha A., Kaiserlingc E., Xiaoc J.X., and Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 50 (2000) 147-160
30. Yin Y., Chen D., Qiao M., Lu Z., and Hu H. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release 116 (2006) 337-345
31. Asghar L.F., and Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J. Pharmacol. Pharm. Sci. 9 (2006) 327-338
32. Dong Y., and Feng S.-S. Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 (2005) 6068-6076
33. Schubbert R., Lettmann C., and Doerfler W. Ingested foreign (phage M13) DNA survives transiently in the gastrointestinal tract and enters the bloodstream of mice. Mol. Gen. Genet. 242 (1994) 495-504
34. Payne R.J.H., Phil D., and Jansen V.A.A. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin. Pharmacol. Ther. 68 (2000) 225-230
35. Payne R.J.H., and Jansen V.A.A. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 42 (2003) 315-325